[1] Hanan N,Shepherd FA,Fossella FV,et al.Randomized phasetrial of pemetrexedversus docetaxel in patients with non-small-cell lung cancer previous treated with chemotherapy[J].J Clin Oncol,2004,22(9):1589-1597.
[2] 张勇,王渭滨,夏晴,等.培美曲塞单药化疗二线治疗老年晚期非小细胞肺癌近期疗效观察[J].西北国防医学杂志, 2015,36(1):53-54.
[3] Johnson DH,Fehrenbacher L,Novotny WF,et al. Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J].J Clin Oncol,2014,22(53):2184-2191.
[4] 高莹,马壮.培美曲塞或吉西他滨联合卡铂治疗老年晚期非小细胞肺癌临床对照研究[J].中国药业,2015,24(12):52-54.
[5] Scagliotti GV,Parikh P,Vonpawel J,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed chemotherapy-native patients with advanced-stage non-small-cell lung cancer[J].J Clin Oncol,2008,26(21):3543-3551.
[6] 李冬杰,李冬雷,李润浦,等.培美曲塞联合奈达铂治疗晚期非小细胞肺癌的临床疗效[J].中国肿瘤临床与康复,2015,22(4):425-427.
[7] Takahashi H, Komaba H, Takahashi Y,et al.Impact of parathyroidectomy on serum FGF23 and so1uble Klotho in hemodialysis patients with severe secondary hyperparathyroidism[J].J Clin Endocrinol Metab,2014,99(42):E652-658.
[8] 郏博, 何小慧, 杨晟, 等. 应用培美曲塞为基础方案化疗的晚期非小细胞肺癌患者EGFR 基因突变与生存的关系[J].中华医学杂志, 2013, 93(46):3659-3662. |
2016, Vol. 33 
